
ABSTRACT Sorfequiline is a novel diarylquinoline in development for treatment of tuberculosis. In vitro data suggest metabolism via CYP3A4, carrying the potential for presystemic metabolism and drug–drug interactions. Its major metabolite, M3, is pharmacologically active. We developed a semi‐mechanistic joint population pharmacokinetic model of sorfequiline and M3 in healthy volunteers. Data were pooled from two studies (CL‐001 and CL‐002). CL‐001 comprised a single‐ascending‐dose part (10–800 mg suspension fasted plus 100 mg fed), a multiple‐ascending‐dose part (25, 75, or 200 mg/day for 14 days, fed), and a relative bioavailability assessment including 100 mg in tablet form under fed and fasted conditions. In CL‐002, fed participants received 200 mg/day suspension for 8 days followed by 165 mg/day for 4 days. Plasma concentrations were quantified using HPLC–MS/MS, and pharmacokinetic modeling and simulations were conducted in NONMEM. A three‐compartment disposition model for both analytes, with transit‐compartment absorption, adequately described the data. A fraction of the dose was assumed to be absorbed as M3 due to gut first‐pass metabolism. This fraction was 46% (95% CI: 41%–50%) in fasted and 15% (13%–19%) in fed participants. Overall bioavailability decreased by 46% (32%–61%) at fasted doses ≥ 400 mg. Model‐based simulations showed that exposures for all investigated regimens remained below safety reference values. Food reduced the fraction of sorfequiline dose absorbed as M3, likely due to limited gut first‐pass metabolism. The developed model provides an initial platform for future pharmacokinetic/pharmacodynamic analyses and simulation of both analytes' exposures under drug–drug interaction scenarios.
Nirmatrelvir/ritonavir is an antiviral agent used against severe acute respiratory syndrome coronavirus 2 infection and inhibits cytochrome P450 3A and P-glycoprotein. The concomitant use of nirmatrelvir/ritonavir markedly increases tacrolimus blood concentrations. Although temporary discontinuation or dose reduction of tacrolimus at the start of nirmatrelvir/ritonavir therapy is recommended in the package insert of this drug, little information is available on tacrolimus dosage adjustment when restarting. In this study, tacrolimus blood concentrations before and after nirmatrelvir/ritonavir co-administration were collected from national university hospitals across Japan, and population pharmacokinetic analysis was performed to develop an optimal dosing strategy for tacrolimus. In total, 83 tacrolimus blood concentrations from 15 patients were used in the analysis. First, the individual pharmacokinetic parameters of tacrolimus before the intake of nirmatrelvir/ritonavir were estimated by post hoc Bayesian analysis using previously reported population pharmacokinetic parameters based on a two-compartment model. The change in the relative bioavailability and clearance of tacrolimus after nirmatrelvir/ritonavir administration was estimated by population pharmacokinetic modeling. Consequently, tacrolimus clearance was considered almost completely inhibited, and relative bioavailability increased 7.99-fold with the co-administration of nirmatrelvir/ritonavir. The optimal dosing strategy based on the simulation was to withhold tacrolimus during nirmatrelvir/ritonavir therapy and to restart tacrolimus at 10% of the baseline dose on day 1, followed by 20% on day 3% and 50% on day 6, and increased to 100% on day 9 after discontinuation of nirmatrelvir/ritonavir, respectively. The proposed strategy will contribute to a safe and effective tacrolimus therapy when used in combination with nirmatrelvir/ritonavir.
ABSTRACT Renal clearance (CLr) is the net outcome of glomerular filtration, secretion, and reabsorption, which makes the quantitative requirements for net renal secretion difficult to infer from simple clearance models. Using a mechanistic kidney model (MechKiM), we simulated blood‐referenced CLr (CLr,b) for 30,000 virtual drugs (neutral, monoanionic, and monocationic) under continuous infusion and across all eight combinations of three proximal‐tubule transporters (basal uptake, basal efflux, apical efflux). Net renal secretion (clearance ratio CR = CLr,b/(fu,b × GFR) > 1.5, where fu,b and GFR are the unbound fraction in blood and the glomerular filtration rate) occurred only when basal uptake transport was present; apical efflux alone produced proximal secretion that was offset by downstream reabsorption, yielding no net secretion. In the scenario where all three transporters were present within the MechKiM framework, five quantitative criteria distinguished secretion‐type drugs, including basal transporter‐mediated uptake (> 4.2 L/h) and its fractional contribution to total basal uptake (> 94% for non‐cationic compounds). Clinical CLr,p (plasma‐referenced CLr) versus in vitro uptake‐transporter data (n = 217) and published MechKiM‐PBPK models (n = 19, typically assigning > 99% of basal uptake to transporters) were consistent with these findings. A sufficient contribution of basal uptake transporters in the proximal tubule is essential for observing net renal secretion. This study provides quantitative, in vitro‐translatable criteria to anticipate renal secretion and transporter‐mediated drug–drug interaction liability.
Exposure-response (ER) analyses assessing the efficacy of large molecule therapeutics are often susceptible to confounding, where associations between drug exposure and patient disease severity can obscure true ER signals and complicate dose selection. To better understand the pharmaceutical industry perspectives on this challenge, the IQ consortium conducted a comprehensive survey targeting clinical pharmacologists, pharmacometricians, and statisticians. The survey, completed by 125 individuals from 23 pharmaceutical companies, aimed to assess awareness, perceived prevalence, mitigation strategies, and the overall role of ER analyses in the context of confounding. Results revealed strong industry awareness, with 88.0% of respondents acknowledging the relevance of ER confounding. However, uncertainty regarding its pervasiveness persists, particularly in non-oncology settings (31.2% unsure). A consensus emerged on the value of dose-ranging study designs as an effective mitigation strategy (81.6% agreement). In contrast, the use of advanced statistical methods for causal inference is inconsistent (45.6% usage), and confidence in their reliability is mixed, with 32.8% of respondents expressing uncertainty and most others rating them only moderate or somewhat reliable. While the majority agreed that confounded ER analyses should be interpreted with caution (79.2%), opinions diverged regarding their value in decision-making when dose-ranging data is insufficient. This uncertainty, coupled with a recognized need for additional alignment with health authorities, led to a call for best-practice guidance (92.8% view as valuable). Overall, the survey findings highlight a need for an industry-wide common approach and the development of clear frameworks to manage and interpret ER confounding for large molecule therapeutics.
ABSTRACT Semi‐mechanistic modeling approaches could be useful for optimal dose selection, and one of the approaches is pharmacokinetic (PK)/receptor occupancy (RO) model for monoclonal antibodies. This study aimed to develop a semi‐mechanistic PK/RO model of S‐531011, a humanized monoclonal antibody against human CCR8 and under development for the treatment of solid tumors, in order to predict human RO values in tumor tissues which are not available in the ongoing clinical study. The model consists of three compartments (central, peripheral, and tumor) and includes four compartments (S‐531011, CCR8, and complexes 1/2 within each compartment). The model parameters were set using available clinical data, non‐clinical data, and physiological information. The human PK/RO model was developed by refinement of a mouse PK/RO model. The time courses of RO values in the tumor compartment were simulated using the model, together with a conservative condition of slow transfer of S‐531011 from blood to the tumor. It was predicted that the RO value in the tumor compartment at 21 days (trough after the third dose after administration of S‐531011 80 mg) would be maintained at > 90% under typical model assumptions. Under the conservative condition, the RO value in the tumor after administration of S‐531011 800 mg would remain at > 90%. The developed semi‐mechanistic PK/RO model could predict human RO values of S‐531011 in tumor tissues. Under typical model assumptions, simulations suggested the dose range of 80–800 mg of S‐531011 every 3 weeks would achieve > 90% RO in tumor tissues.